Lunai Bioworks Reports Service Revenue Growth and Reduced Net Loss in Latest Financial Results

Lunai Bioworks Inc. (formerly Renovaro Inc.) reported its financial results for the three and nine months ended March 31, 2026, revealing a service revenue of $20,942, a significant increase from zero revenue in the same period last year. The company’s net loss for the quarter was $2.57 million, compared to a net income of $189,176 in the prior year, marking a substantial shift in profitability. For the nine-month period, the net loss decreased to $1.55 million from $51.28 million, primarily due to a reduction in operating expenses and a gain from the bankruptcy of a subsidiary.

Total operating expenses for the three months ended March 31, 2026, were $1.45 million, down 65% from $4.16 million in the same quarter of 2025. This decrease was largely attributed to a reduction in general and administrative expenses, which fell by 66% to $1.42 million, and a significant drop in research and development costs. The company reported a goodwill impairment of $47.61 million in the previous year, which was not present in the current reporting period, contributing to the overall reduction in losses.

Lunai Bioworks has undergone significant organizational changes, including the acquisition of BioSymetrics, Inc. in April 2025, which has been integrated into its operations. The company also deconsolidated Gedi Cube B.V. following its bankruptcy in September 2025, resulting in a gain of $12.02 million recognized in the nine-month results. The company’s total assets increased to $9.86 million as of March 31, 2026, compared to $8.23 million at the end of the previous fiscal year, primarily due to an increase in cash and cash equivalents.

The company’s cash position improved significantly, with cash and cash equivalents rising to $3.16 million from $92,700 at the end of June 2025. However, Lunai Bioworks reported a working capital deficit of $15.55 million, raising concerns about its ability to continue as a going concern. Management has indicated plans to secure additional funding through equity or debt financing to support ongoing operations and product development, although there is no assurance that such funding will be available on favorable terms.

Looking ahead, Lunai Bioworks aims to focus on the development and commercialization of its AI-driven diagnostics and therapeutic platforms, particularly in neurology and oncology. The company is actively seeking to expand its market presence and improve its financial stability, but it acknowledges the challenges posed by its current financial condition and the need for further capital to sustain operations.